Debiotech takes ST by hand and adopts nanotechnology and develops enormous disposable insulin that breaks through to inject
Debiotech and purpose law semiconductor announce both sides sign one and make strategy cooperative agreement which is sold the unique miniature insulinogenic syringe pump. The nanometer pump one because of the intersection of micro flow control and MEMS ' Micro-Electro-Mechanical System) Technical innovative concept, design concept to install, stick at the cloth giving glycosuria disease to infuse insulin one miniature syringe pump continuously in lump-sum skin. This nanometer pump will help to promote new technical usability, quality of the life which treat efficiency and diabetic greatly. The original technology of this product has got 2006 Swiss scientific award, the agreement signed today made this technology closer to the goal of industrialization more.
Insulinogenic syringe pump treatment or injecting insulin (CSII) subcutaneously continuously Can substitute the single stepping method that must infuse several insulin in one day, this kind of treatment is being favoured by people. According to CSII therapeutic method, the diabetic needs to connect a programming syringe pump, syringe pump with one liquid storing irritate, link, insulin inculcate from these liquid storing with the note in the human hypodermis, infuse the course of secreting insulin naturally like the pancreas continuously in a whole day.
The high lump-sum insulinogenic syringe pump of micromation merge insulin of Debiotech infuse technology and ST, make the intersection of micro flow control and operational capacities of chip on a large scale. Little fluidics can control the size very little flow of liquid through electronic way. This syringe pump indicates CSII treatment takes a great step forward in developing and employing, and this sophisticated technology will be also applied to other biochemical applications.
Today, the Off-The-Shelf insulinogenic syringe pump magnitude is equivalent to a BP. This new Debiotech micromation MEMS products that are made by ST, the size is probably 1/4 of the existing syringe pump, the form of sticking the cloth with the skin is worn on people, the human eye can hardly see its existence. Whether the erection site that disease needed to pay attention to the syringe pump was suitable in the past, hide the pump under the clothes, the small and exquisite size of the new product no longer lets disease worry about this.
In addition, adopt the injection dosage of the insulin that MEMS technical nanometer pump can also control the doctor to require accurately. The precision of the dosage is a key factor of determining the level of curative effect, and contribute to the negative function that reduces medicines and infuses for a long time. The control accuracy that the nanometer pump infuses to the liquid can reach and receive to rise, this level is very close to human insulin to infuse. Product this can prevent medicine to be excessive, measure the intersection of syringe pump and the intersection of traditional Chinese medicine and the intersection of pharmaceutical and enough, blocks, bubble and other potential troubles, in order to further protect a patient. In addition, adopt technical disposable products of large-scale semiconductor manuafcture as one, this cost based on nanometer syringe pump of MEMS is very cheap too, so, disease or health care system does not need to pay the existing syringe pump solution common earlier stage and make the investment.
This indicates from Debiotech development, insulinogenic syringe pump of ST industrialization micro flow control MEMS technology is applied to diabetes and treats the field for the first time. The function sample wafer of the nanometer pump has already gone into operation, the products of complete industrialization which the two sides concerned expect to sell in the form of disposable liquid storing box for the appointed market supply after 2008. Debiotech will take the form authorized to the leading firm on the market of medical equipment to sell the products when the time comes.
The industrialization of the new product will fully utilize the manufacture experience that ST will be accumulated on the biochemical market constantly. ST the intersection of micro flow control and other the intersection of biotechnology and project of product division it includes to be mainly the intersection of experiment and platform at the used for measuring pyemiapyaemia and bird flu the intersection of In-Check and block at present also.
Additional remarks
About 250 million persons catch diabetes in the whole world at present, as population increases, senilization and change of life style, it is estimated patient's number will still continue increasing over the next ten years. Get appropriate treatment, diabetes may cause cardiovascular disease, renal failure, lose one's sight and nerve damage up to the death. Diabetes is one of the main causes of disease which causes the death in the western developed country.
The insulinogenic syringe pump treats the market and grows at top speed: According to HSBC1, before 2009, the global insulinogenic syringe pump will treat the market and can be expected to rise to 1,600 million dollars from 800 million dollars in 2004.